Atzumi™ (dihydroergotamine (DHE)) nasal powder
Approval Date: Apr 2025
While DHE has been available since 1946, this is the first DHE drug available in a nasal powder formulation and indicated for the acute treatment of migraine with or without aura
Brekiya® (dihydroergotamine mesylate) injection
Approval Date: May 2025
While DHE has been available since 1946, this is the first DHE drug available in a ready-to-use autoinjector, indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches
Symbravo® (meloxicam and rizatriptan) tablets
Approval Date: Jan 2025
A combination NSAID and triptan drug indicated for the acute treatment of migraine with or without aura
Zavzpret™ (zavegepant) nasal spray
Approval Date: Mar 2023
Indicated for the acute treatment of migraine with or without aura
Eprontia™ (topiramate) oral solution
Approval Date: Nov 2021
Indicated for the treatment of seizures, and for the preventive treatment of migraine
Zomig® (zolmitriptan) nasal spray
Approval Date: Sep 2021
Indicated for the acute treatment of migraine with or without aura
Trudhesa™ (dihydroergotamine mesylate) nasal spray
Approval Date: Sep 2021
Indicated for the acute treatment of migraine with or without aura
Qulipta™ (atogepant) tablets for oral use
Approval Date: Sep 2021
Indicated for the preventive treatment of episodic migraine
